Frontotemporal dementia (FTD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Frontotemporal dementia (FTD)

Frontotemporal dementia (FTD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Frontotemporal dementia (FTD) is a focal clinical syndrome characterised by profound changes in personality and social conduct and associated with circumscribed degeneration of the prefrontal and anterior temporal cortex. Frontotemporal disorders can be grouped into three types-

Progressive behavior/personality decline- changes in personality, behavior, emotions, and judgment (called behavioral variant frontotemporal dementia).

Progressive language decline— early changes in language ability, including speaking, understanding, reading, and writing (called primary progressive aphasia).

Progressive motor decline—characterized by various difficulties with physical movement, including the use of one or more limbs, shaking, difficulty walking, frequent falls, and poor coordination (called corticobasal syndrome, supranuclear palsy, or amyotrophic lateral sclerosis).

Thelansis Epidemiology study indicates In the USA the prevalence of FTD between the ages of 45–65 years ranged from 15 to 22 per 100,000 people, with incidence estimates ranging from 2.7 to 4.1 per 100,000 members in the same age range.

Competitive landscape of FTD includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of FTD across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

FTD Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake , Attribute Analysis , Analog Analysis , Disease burden and pricing scenario, Summary and Insights.

Read more: Frontotemporal dementia (FTD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

S. No        Asset        Company         Stage

1        PR006        Prevail Therapeutics  Phase 2

2        AL001        Alector Inc.                Phase 3

3        TRx0237        TauRx Therapeutics Ltd Phase 3

4        galantamine hydrobromide   Johnson & Johnson Phase 2

5        Flortaucipir F18        Avid Radiopharmaceuticals Phase 1

6        memantine hydrochloride        H. Lundbeck A/S   Phase 3

7        Hydroxypropyl-beta-cyclodextrin         CTD Holdings, Inc.  Phase 2

8        FRM-0334  FORUM Pharmaceuticals Inc  Phase 2

9        IB1001        IntraBio Inc                Phase 2

10        arimoclomol        Orphazyme                Phase 3

11        Adrabetadex        Vtesse, Inc.,        Phase 3

12        AADvac1 40 µg        Axon Neuroscience SE   Phase 1

13        hematopoietic stem cell infusion   Talaris Therapeutics Inc. Phase 2

14        GZ402665        Genzyme, a Sanofi Company        Sanofi        Phase 2

15        miglustat        Actelion                Phase 2 

16        Pimavanserin        ACADIA Pharmaceuticals Inc. Phase 3

17        Sebelipase alfa (SBC-102)        Alexion Pharmaceuticals  Phase 3